好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

At-Home Telespirometry [AHT] in Amyotrophic Lateral Sclerosis [ALS]
Neuromuscular and Clinical Neurophysiology (EMG)
P8 - Poster Session 8 (11:45 AM-12:45 PM)
10-003

We measured erect seated FVC [eFVC] and supine FVC [sFVC] using in-clinic-conventional [Viaire and Vyasis, USA], in-clinic-portable and at-home-portable [MIR Spirobank Smart, Italy] spirometers with in-person and internet-based respiratory therapist coaching.

We adapted baseline eFVC in an algorithm to facilitate prognostication of individual patients and customize management strategies as described for lung transplantation patients [Mohanka 2000] and ALS [Elamin 2018, Torrieri 2022].

Classification of disease progression based on stratified forced vital capacity is a model used to identify clinical phenotypes in ALS [Ackrivo 2019]. Remote monitoring of FVC using internet-based system is a validated method in primary pulmonary disorders, but not in ALS.

Electronic health records of 22/95 ALS clinic patients (23%) from single ALS center that launched AHT between July 2020 to June 2021 was reviewed in this IRB-approved retrospective study. Patients were stratified according to baseline eFVC >=80 %, 60%-80%, <=60% predicted.

eFVC acquired within a 7-day period (N=16) were highly correlated in liters [R2=0.926; p<0.0001] and %p [R2=0.922, p < 0.001]. Bland-Altman analysis showed a mean difference of 0.15L [conventional – portable]; 95% limits of agreement =-0.40L to 0.70L; 2.7 %p [-12.1% to 17.5%].

eFVC < 60 %p at baseline entry had statistically significant [ < 60 %p mean = 766 days, 95%CI= 368 to 1162 days; > 60 %p mean = 2638 days, 95%CI = 1479 to 3797 days; HR = 0.2218 95% CI = 0.07614 to 0.8008; P = 0.0215] decreased survival compared with the upper tertiles combined.  

We are conducting a larger prospective confirmatory study [NCT05106569] to validate AHT measurement of SVC [slow vital capacity] to determine if a higher level of peak lung functions at ALS diagnosis would be associated with longer survival and better outcomes in relation to overall respiratory care management.

Authors/Disclosures
Eufrosina I. Young, MD (Upstate University Hospital)
PRESENTER
The institution of Dr. Young has received research support from Mitsubishi Tanabe Pharma America.
Jenny Meyer, MD (Upstate Medical University) The institution of Dr. Meyer has received research support from Grifols. The institution of Dr. Meyer has received research support from Medicinova.
Dongliang Wang Dongliang Wang has nothing to disclose.
Bhavya Narapureddy, MBBS (Upstate Medical University) Dr. Narapureddy has nothing to disclose.
Birendra Sah (Upstate Medical University) Birendra Sah has received publishing royalties from a publication relating to health care.
Dragos Manta Dragos Manta has nothing to disclose.
Urvi G. Desai, MD, FAAN (Dept of Neurology, CMC) Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.